Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid–Related Disease

2019/03/20 by Dong Kyu Kim, Keun‐Ho Lee, Keun-Ho Lee +11 · 11 citations
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastroesophageal reflux and treatments #Potassium and Related Disorders

paper · pdf · doi:10.1124/jpet.118.254904

Cited by

• Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors
• Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. [europepmc]
• 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. [europepmc]
• Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function. [europepmc]
• Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages. [europepmc]
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. [europepmc]
• Structure Determination of Tegoprazan(( S )-4-((5,7-difluorochroman-4-yl)oxy)- N , N ,2-trimethyl-1 H -benzo[ d ]imidazole-6-formamide) Polymorphs A and B by Laboratory X-Ray Powder Diffraction. [europepmc]
• Comprehensive Investigation of Polymorphic Stability and Phase Transformation Kinetics in Tegoprazan. [europepmc]
• Tegoprazan as First- and Second-Line Therapy for Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. [europepmc]
• [Impact of P-CABs in the Treatment of Acid-related Diseases: an Evidence Review]. [europepmc]
• Comparative renal safety: potassium-competitive acid blockers vs proton pump inhibitors. [europepmc]